Psoriasis Clinical Trial

A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis

Summary

This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subjects with chronic plaque psoriasis aged 18 to 75 who have had insufficient response to topical agents, and who meet the psoriasis assessment expectations as defined in the study protocol

Exclusion Criteria:

Females who are pregnant or breastfeeding
Men and women who cannot comply with requirements to avoid fathering a child or becoming pregnant, respectively
Subjects treated with leflunomide or other biological therapies to treat psoriasis and all JAK-STAT inhibitors within 12 weeks prior to first dose of study drug

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

50

Study ID:

NCT01634087

Recruitment Status:

Completed

Sponsor:

Incyte Corporation

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You


Hot Springs Arkansas, , United States

Los Angeles California, , United States

Clinton Minnesota, , United States

Fridley Minnesota, , United States

Rochester New York, , United States

Moncton New Brunswick, , Canada

Windsor Ontario, , Canada

Montreal Quebec, , Canada

Quebec , , Canada

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

50

Study ID:

NCT01634087

Recruitment Status:

Completed

Sponsor:


Incyte Corporation

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider